Exploring Linvoseltamab (LINVO) and Carfilzomib (CFZ) combination in relapsed/refractory multiple myeloma (RRMM) via LINKER-MM2 trial. Assessing safety, efficacy, and pharmacokinetics with promising initial outcomes: high response rates (ORR 91-100%), manageable toxicity (neutropenia, thrombocytopenia), and durable responses. Supports continued investigation into LINVO + CFZ for advanced MM treatment.

Key Points:

• Research Problem/Question: Assess LINVO + CFZ safety and efficacy in RRMM.
• Methodology: Phase 1b, open-label LINKER-MM2 trial evaluating dose escalation.
• Key Findings: High ORR (91-100%), durable responses, manageable toxicity profile.
• Significance/Impact: Promising regimen for advanced MM; supports further clinical development.

Conclusion:
Linvoseltamab combined with carfilzomib demonstrates potent anti-myeloma activity with manageable adverse events, encouraging continued exploration in treating relapsed/refractory multiple myeloma.

Authors:
Salomon Manier,  Enrique Ocio,  Carmen Martínez-Chamorro,  Sosana Delimpasi,  Albert Oriol,  Meletios Dimopoulos,  Xavier Leleu,  Samuel Rubinstein,  Nisha Joseph,  Mercedes Gironella Mesa,  Rajshekhar Chakraborty,  Carlos Fernández de Larrea,  Aurora Breazna,  James Drew,  Anita Boyapati,  Anasuya Hazra,  Glenn Kroog,  Shawn Sarkaria,  Paula Rodríguez-Otero